Doseology Sciences's revenue for the
three
months ended in Mar. 2026 was $0.02 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06 Mil.
Doseology Sciences's Revenue per Share for the
three
months ended in Mar. 2026 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01.
Warning Sign:
Doseology Sciences Inc revenue per share is in decline over the past 12 months.
During the past 6 years, Doseology Sciences's highest 3-Year average Revenue per Share Growth Rate was 31.00% per year. The lowest was 31.00% per year. And the median was 31.00% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Doseology Sciences Revenue Related Terms
Doseology Sciences Revenue Historical Data
* Premium members only.
The historical data trend for Doseology Sciences's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Doseology Sciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doseology Sciences Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Doseology Sciences's Revenue distribution charts can be found below:
* The bar in red indicates where Doseology Sciences's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Doseology Sciences (DOSEF) has a Revenue of $0.06 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Doseology Sciences and its competitors.
Is Doseology Sciences' Revenue too high?
Doseology Sciences' current Revenue is $0.06 Mil. Overall, Doseology Sciences has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Doseology Sciences' Revenue compare to VRTX and REGN?
Doseology Sciences' Revenue of $0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Doseology Sciences and its competitors. Doseology Sciences's current Revenue is $0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doseology Sciences stock overvalued right now?
Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.29, compared to a current price of $0.11 — trading 61.3% below its estimated fair value. The current Revenue is $0.06 Mil. Doseology Sciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current Revenue is $0.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doseology Sciences (DOSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued.
The current stock price of $0.11 is trading 61.3% below its estimated GF Value™ of $0.29.
GuruFocus considers Doseology Sciences to be Possible Value Trap.
Key valuation signals for DOSEF:
Revenue: $0.06 Mil
GF Value™: $0.29 vs. price of $0.11 (61.3% below fair value)
No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.
31GF Score
Get the complete analysis for DOSEF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOSEF has been successfully added to your 
